Hi BDAZ. Thanks for this perspective.

I'm wondering if you have a sense of where the scientific community is regarding the awareness, knowledge about and interest in epigenetics in general and in terms of treating various medical conditions such as cancers and CVD?

I have an impression that within the scientific community there is limited knowledge about epigenetics and for those aware of the progress it seems like "the jury is still out".

I do not sense that there is an underlying momentum in the development of epigenetic approaches. It seems like a few companies are checking it out but there is no rapid "diving in" to take the lead (other than RVX??? and a few companies using the benzodiazepine scaffold with limited success).

Even with rvx-208 it wasn't until ASSURE was considered a failure that RVX really dug in to find out first the MACE reduction finding and then for RVX to make significant progress regarding the complex MOA of rvx-208's multiple epigenetic cascading effects on MACE.

So it really does seem that RVX may have the lead in terms of understanding BET inhibition (as Don always claims). An implication is that it will take time for the scientific and investment communities to catch up. Of course a successful BoM will probably drive the momentum but I wonder if the science people are catching on?

So do you have a sense to the "epigenetic state of the nation"?

Regards

Toinv